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Abstract
Objectives The aim of this study was to clarify the
characteristics of regional cerebral glucose metabolic
abnormalities in patients with malignant lymphoma of the
body using statistical image analyses. Post-therapeutic
changes in cerebral glucose metabolism were also
evaluated.
Methods The subjects consisted of 30 patients, including
16 patients with diffuse large B-cell lymphoma and 14
patients with other types of lymphoma. Patients with pri-
mary cerebral lymphoma were excluded from this study.
All patients underwent CT and whole-body FDG-PET
scans, including 4-min brain scans using a dedicated PET/
CT scanner during both the pre- and post-treatment peri-
ods. The whole-body scans started 60 min after the
administration of 185 MBq of FDG, after which the brain
data were extracted from whole-body data. The degree of
regional cerebral glucose metabolism was evaluated on a
voxel-by-voxel basis using statistical parametric mapping
(SPM). The total tumor glycolytic volume of the body was
measured using a separate workstation. The normal control
subjects were 12 persons who underwent medical check
with FDG-PET/CT and had no lesions suggesting malig-
nant tumor.
Results The level of regional cerebral glucose metabo-
lism decreased in association with an increase in the total
glycolytic volume in the bilateral frontal and parietal cor-
tices. After chemotherapy, the statistical image analysis
demonstrated an interval recovery of the cerebral glucose
metabolism of the bilateral parietal and occipital cortices in
the good responders, whereas there were no significant
differences observed in regional cerebral glucose metabo-
lism between the pre- and post-treatment images in the
poor responders. Comparison between normal control
subjects and patients with pre-treatment lymphoma also
showed that the regional cerebral glucose metabolism
decreased in the parieto-occipital cortices in patients with
lymphoma compared to normal control subjects.
Conclusions We demonstrated that patients with malig-
nant lymphoma of the body exhibited abnormal regional
cerebral glucose metabolism, which improves after che-
motherapy. Although the mechanism underlying the
reduction of cerebral glucose metabolism remains unclear,
our findings indicate the functional alternation and/or
subclinical damage of the brain in patients with malignant
lymphoma.
Keywords Malignant lymphoma  FDG-PET/CT 
Paraneoplastic syndrome  Regional cerebral glucose
metabolism  Statistical image analysis
Introduction
It is well known that some of the cancer patients exhibit
neuropsychiatric symptoms without apparent involvement
of the tumor with the central nervous system, so-called
paraneoplastic syndrome (PNS) [1]. We experienced a
patient with malignant lymphoma of the body who dis-
played bilateral fronto-parieto-occipital hypometabolism
without apparent abnormalities on brain MRI. Regarding
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cerebral glucose metabolism in patients with malignant
lymphoma, it has previously been reported that the global
FDG uptake of the brain decreases in correlation with the
total glycolytic volume (TGV) of the body [2]. However,
there are no descriptions regarding regional changes in
cerebral glucose metabolism. We retrospectively evaluated
regional glucose metabolism in patients with malignant
lymphoma of the body and attempted to elucidate the
characteristics of regional cerebral glucose metabolic
abnormalities using statistical image analysis. Post-thera-
peutic changes in the cerebral glucose metabolism were
also evaluated.
Materials and methods
The subjects consisted of 30 patients (30–86 years old,
average: 56.4 years old, 15 females and 15 men) who
underwent dedicated FDG-PET/CT for the pre-treatment
staging of malignant lymphoma of the body, including 16
patients with diffuse large B-cell lymphoma, five patients
with natural killer cell T-cell lymphoma, three patients
with follicular lymphoma, three patients with Hodgkin’s
lymphoma, two patients with T-cell lymphoma and one
patient with intravascular large B-cell lymphoma. The
patients were classified as having stage I (four patients),
stage II (eight patients), stage III (eight patients) and stage
IV (10 patients) disease according to the revised Ann Arbor
classification proposed by Cotswold [3]. The therapeutic
response was a complete response (CR) in 19 patients,
partial response (PR) in eight patients and progressive
disease (PD) in three patients based on the International
Working Group response criteria [4]. All patients under-
went FDG-PET/CT during both the pre- and post-treatment
periods. The treatment regimens included chemotherapy
(rituximab, cyclophosphamide, doxorubicin, vincristine
and prednisone; R-CHOP: 16 patients, cyclophosphamide,
doxorubicin, vincristine, and prednisone; CHOP: three
patients, adriamycin, bleomycin, vinblastine, and dacar-
bazine; ABVD: two patients and dexamethasone, etopo-
side, ifosfamide and carboplatin; DeVIC: two patients),
radiation therapy (one patient) and surgical therapy (one
patient). Five of the 30 patients underwent brain MRI. The
normal control subjects were 12 persons (42–80 old years,
average: 62.0 years old, 8 females and 4 men) who
underwent medical checkup with FDG-PET/CT and had no
lesions suggesting malignant tumor. Patients with primary
cerebral lymphoma or apparent cerebral abnormalities,
such as cerebral infarcts more than 10 mm in diameter on
CT or MRI, were excluded from this study. Subjects with
apparent miss-registration between the FDG-PET and CT
images due to head movement during the examinations
were also excluded based on a visual inspection of the
integrated PET/CT images. Subjects with a blood sugar
level over 120 mg/dl were excluded to prevent the effects
of hyperglycemia on the FDG brain uptake. The blood
sugar levels of 30 patients ranged from 68 to 119 mg/dl
(mean ± SD: 92.1 ± 13.1 mg/dl) in the pre-treatment
period and from 65 to 119 mg/dl (mean ± SD:
92.1 ± 12.5 mg/dl) in the post-treatment period. Those of
controls subjects were from 63 to 116 mg/dl (mean ± SD:
92.3 ± 14.9 mg/dl). No subjects received psychotropic
drugs, such as sedatives, at the time of the PET studies. The
interval between the pre- and post-treatment FDG-PET/CT
scans ranged from 2.9 to 20 months (mean ± SD:
7.9 ± 3.6 months).
FDG-PET/CT
After fasting for at least 4 h, each subject received an
intravenous infusion of 185 MBq of FDG over 2 min while
sitting in a chair, then was moved to a semi-dark room and
placed in the supine position on a reclining seat for 60 min.
The PET/CT scanner used in this study was the Aquiduo
(Toshiba/Siemens Co. Ltd). First, non-contrast whole-body
CT data were obtained in helical mode with an X-ray tube
voltage peak of 120 keV, a flexible X-ray tube current of
50–400 mA, a field of view of 500 9 500 mm, and a
reconstructed slice thickness of 2 mm. The whole-body
PET scan was started 60 min after the administration of
FDG. The subjects were asked to breathe normally during
PET acquisition, and FDG-PET data were collected in the
three-dimensional imaging mode for 2 min at each position
from foot to head; thus, the brain data were obtained from
76 to 80 min after the administration of FDG. The PET
data were reconstructed using a CT transmission map for
attenuation correction with the ordered-subsets expectation
maximization algorithm (4 iterations, 14 subsets) and a
Gaussian Filter (FWHM = 7.0 mm) and displayed in a 128
matrix (pixel size = 3.9 9 3.9 mm with a slice thickness
of 2.0 mm).
Data analysis
The brain data were extracted from the whole-body data,
and brain images in the Digital Imaging and Communica-
tions in Medicine (DICOM) format were converted to the
analyze format using MRlcro (Chris Rorden’s MRIcro,
Copyright 1999–2005, all rights reserved.) on a worksta-
tion, after which clipping and centering of the images were
performed. Anatomical normalization into the MNI stan-
dard space (Montreal Neurological Institute, McGill Uni-
versity, Montreal, Canada) was performed with the
Statistical Parametric Mapping 2 software package (SPM2,
Welcome Department of Cognitive Neurology, London,
UK) and FDG template running under MATLAB R2009a
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(Math Works Inc., Sherborn, MA, USA). Spatially nor-
malized images were smoothed via convolution using an
isotopic Gaussian kernel with a 12-mm full-width half-
maximum. Statistical comparisons were made on a voxel-
by-voxel basis using SPM8 to generate SPM (t) maps. A
multiple regression analysis was used to evaluate the cor-
relations between the degree of regional cerebral glucose
metabolism and other parameters, including TGV and the
clinical stage. The two-tailed paired t test was used to
compare the brain images between the pre- and post-
treatment examinations. The resulting maps of t statistics
were displayed at height thresholds of p \ 0.005 (paired
t test), uncorrected for multiple comparisons between the
pre-treatment and post-treatment patients, and displayed at
height thresholds of p \ 0.02 (non-paired t test), uncor-
rected for multiple comparisons between normal control
subjects and patients with lymphoma. The extent threshold
of 200 voxels was also used to determine the statistical
significance of the cluster.
Measurement of the total glycolytic volume
The TGV of the body was measured using a separate
workstation (Virtual Place, AZE, Japan). The tumor vol-
umes were measured semiautomatically using ROIs set on
the whole-body images. A threshold was determined at the
level of 2.5 of SUV [5], and areas with a higher FDG
uptake were automatically extracted, while the areas of
physiological FDG uptake were manually eliminated.
Finally, both the total volume of the areas over the
threshold and the mean SUV were measured. The TGV
was calculated according to the following equation:
TGV = tumor volume 9 mean SUV [2]. The study pro-
tocol was approved by the Independent Ethics Committee/
Institution Review Board of Fukuoka University Hospital.
Results
A significant negative correlation was observed between the
average cerebral SUV and the TGV (y = -0.0001x ? 6.25,
R2 = 0.22, p \ 0.001). The average cerebral SUV was also
correlated with the clinical stage (y = -0.57x ? 7.34,
R2 = 0.18, p \ 0.001). The correlation between local cere-
bral glucose metabolism and the TGV is shown in Fig. 1. The
statistical image analysis demonstrated that the bilateral
frontal temporal and parietal glucose metabolism was nega-
tively correlated with the TGV. The brain areas showing
peak coordinates are summarized in Table 1. Tables 2 and 3
present the areas with significant differences in regional
cerebral glucose metabolism between the pre- and post-
treatment examinations in the patients with a therapeutic
response of CR. After chemotherapy, the degree of regional
cerebral glucose metabolism significantly improved in the
bilateral parietal and occipital (Fig. 2a) and decreased in the
bilateral cerebellar hemisphere, right putamen, bilateral
insula and bilateral anterior cingulate regions (Fig. 2b). The
regional cerebral glucose metabolism in pre-treatment
patients decreased in the left parietal and bilateral occipital
regions compared to that in normal control subjects (Fig. 3a),
and it increased in the right frontal region and bilateral cer-
ebellar hemispheres (Fig. 3b). The brain areas showing peak
coordinates are summarized in Tables 4 and 5. There were
no significant changes in regional cerebral glucose metabo-
lism between the pre-and post-chemotherapy examinations
in the patients with a therapeutic response of PR or PD.
Case presentation
Case 1 A 59-year-old male was admitted to Fukuoka
University Hospital for an examination of the cause of a
Fig. 1 Images of brain regions
showing a significant
correlation between regional
cerebral glucose metabolism
and the TGV. The presence of
bilateral frontal, temporal and
parietal glucose metabolism was
negatively correlated with the
TGV
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persistent high fever lasting for 3 weeks in addition to
severe liver dysfunction. There were no neurological
deficits; however, the patient reported a feeling of
dullness in his head. FDG-PET revealed a high FDG
uptake in the liver and right femoral bone marrow
(Fig. 4a), as well as bilateral parieto-temporal-occipital
hypometabolism (Fig. 4b–d). The cerebral glucose
metabolism was relatively preserved in the bilateral
primary sensory motor cortices and cerebellum. The
patient’s blood sugar level was 96 mg/dl. Subsequent
brain MRI did not show any abnormalities (Fig. 4e).
Therefore, a diagnosis of intravascular lymphoma (IVL)
was highly suspected. A needle biopsy confirmed a
diagnosis of IVL of the liver (diffuse large cell type).
Following the administration of chemotherapy with
prednisolone (PSL), etoposide (VP-16) and R-CHOP,
the patient’s clinical symptoms and laboratory data
markedly improved. The feeling of dullness in his head
also disappeared after treatment. Post-treatment FDG-
PET/CT revealed no areas of abnormal uptake in the
liver or bone marrow (Fig. 5a), and no apparent
hypometabolism was observed in the brain (Fig. 5b–d).
The patient’s blood sugar level was 91 mg/dl at the time
of the second PET study.
Case presentation
Case 2 A 35-year-old male complained of systemic
arthralgia persisting for 2 weeks. His condition spontane-
ously improved; however, bilateral hearing loss subse-
quently developed. The patient exhibited weight loss of
10 kg within 1 month. Therefore, he was admitted to Fu-
kuoka University Hospital for a further examination. His
laboratory data revealed elevated serum levels of LDH
(200 IU/l), ferritin (70,000 ng/ml), GOT (308 IU/l) and
GPT (236 IU/l), suggesting hepatic damage. FDG-PET
showed a high FDG uptake in the lymph nodes throughout
the body, spleen and right femoral bone marrow (Fig. 6a).
The level of cerebral glucose metabolism was decreased in
the bilateral parieto-occipital association cortices (Fig. 6b–
d). The blood sugar level was 85 mg/dl, and subsequent
brain MRI did not show any abnormalities (Fig. 6e). A
Table 1 Location of brain
areas showing a negative
correlation between cerebral
glucose metabolism and the
total glycolytic volume (TGV)
p \ 0.005, uncorrected for
multiple comparisons
a Coordinated in the Talairach
space
–
–
–
–
–
–
–
–
–
–
–
–
–
Table 2 Locations of brain
areas showing an interval
increase in cerebral glucose
metabolism after therapy in
patients with a therapeutic
response of CR
p \ 0.005, uncorrected for
multiple comparisons
a Coordinated in the Talairach
space
–
–
–
–
–
–
–
–
–
–
–
–
–
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bone marrow biopsy revealed the involvement of T-cell
lymphoma. Following the administration of chemotherapy
with CHOP, the patient’s clinical symptoms and laboratory
data markedly improved. Post-treatment FDG-PET/CT
showed no areas of abnormal uptake in the systemic lymph
nodes, spleen and bone marrow (Fig. 7a) with improved
cerebral glucose metabolism (Fig. 7b–d).
Discussion
In the present study, we confirmed the findings of a report
by Hanaoka et al. [2] that indicated that the mean cerebral
SUV of FDG is correlated with the total glycolytic volume.
In addition, we demonstrated that the regional cerebral
glucose metabolism changes in association with the TGV
in patients with malignant lymphoma of the body, namely,
a negative correlation between the degree of cerebral glu-
cose metabolism and the total glycolytic volume was
observed in the bilateral frontal, temporal and parietal
cortices. After chemotherapy, this finding improved in the
good responders. The comparison of regional cerebral
glucose metabolism between normal control subjects and
the pre-treatment patients also showed similar results.
Namely, regional cerebral glucose metabolism decreased in
the parietal and occipital regions in patients with lym-
phoma, although the significant level was lower in the
latter. These results highly suggest that regional cerebral
metabolic changes are caused by the presence of malignant
lymphoma lesions. To the best of our knowledge, this is the
first report of regional cerebral metabolic changes in
patients with malignant lymphoma of the body evaluated
using statistical image analysis.
Several explanations can be considered regarding the
mechanisms underlying the regional decrease in cerebral
glucose metabolism. One of the most plausible
mechanisms is the presence of intravascular involvement
of lymphoma cells, although only one patient of 30 patients
was diagnosed with IVL. IVL is a relatively rare clinical
entity [6] characterized by occlusion of the arterioles,
capillaries and venules due to the proliferation of malignant
lymphomatous cells [6, 7]. According to the WHO classi-
fication, this condition is a subtype of diffuse large-cell
lymphoma [8]. When the central nervous system is
involved, clinical symptoms, such as stroke or dementia,
may occur. The parietal cortices are located in the distal
portion of the middle cerebral arteries and posterior cere-
bral arteries, so-called ‘‘watershed areas’’. Occlusion of the
small arteries may induce ischemia in neurons and neuro-
nal dysfunction, as well as decreased cerebral glucose
metabolism. However, almost all cases in previous reports
of central nervous system involvement of IVL were asso-
ciated with neurological deficits or organic lesions on CT/
MR images. As shown in the case presentation section
(Figs. 4, 5), the degree of cerebral glucose metabolism
decreased without apparent cerebral lesions on MRI in this
study. Regarding the FDG-PET findings of malignant
lymphoma, it is well known that primary cerebral lym-
phoma exhibits a higher FDG uptake in the lesions than in
the cerebral cortices [9], and it has also been reported that
cerebral involvement of malignant lymphoma is associated
with a high FDG uptake [10]. If the decrease in cerebral
glucose metabolism is caused by IVL involvement, it may
be possible to successfully demonstrate functional alter-
nations of the brain in the preclinical stage of intravascular
involvement with lymphoma cells.
Another possible mechanism is an auto-immunogenic
reaction known as paraneoplastic syndrome [7]. PNS is
detected in less than 0.1 % of patients with malignant
tumors [11], such as small-cell lung cancer, thymoma,
breast cancer, ovarian cancer and malignant lymphoma. A
diagnosis of PNS is confirmed when the symptoms
Table 3 Locations of brain
areas showing an interval
decrease in cerebral glucose
metabolism after therapy in
patients with a therapeutic
response of CR
p \ 0.005, uncorrected for
multiple comparisons
a Coordinated in the Talairach
space
–
–
––
–
–
–
–
–
–
–
–
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disappear following the removal or shrinkage of the tumor
[12]. Voltz [13] reported that cerebellar glucose metabo-
lism is decreased in patients with PNS. PNS is also caused
by cytokines secreted from the activated of immune system
cells, such as natural killer cells, due to the existence of
tumor cells. Regarding this point, the brain function and
metabolism are affected in patients with autoimmune dis-
eases, such as Hashimoto’s or Basedow’s disease [14]. As
shown in case 2, cerebral metabolic abnormalities can
occur in patients with malignant lymphomas other than
intravascular lymphomas. Therefore, this mechanism may
function in cases of malignant lymphoma. The parietal and
occipital association cortices play an important role as the
center of visuospatial recognition. These areas share many
neuronal connections with other parts of the brain via
synaptic transmission. Antibodies associated with tumors
may induce cross talk with neuronal structures, such as
synapses or axons. These areas are frequently affected in
patients with Alzheimer’s disease [15]; thus, involvement
of the parietal cortices may cause dementia. As no patients
presented with apparent symptoms of dementia in the
present study and the decrease in cerebral glucose metab-
olism caused by Alzheimer’s disease is usually progressive
and irreversible, it is unlikely that the decrease in cerebral
glucose metabolism is caused by occasional coincident
dementia.
Fig. 2 Images of brain regions
showing significant differences
in cerebral glucose metabolism
between the pre- and post-
treatment examinations. The
level of cerebral glucose
metabolism was significantly
increased in the bilateral
parietal and occipital regions
after treatment (a) and
decreased in the bilateral
cerebellar hemisphere, right
putamen, bilateral insula and
bilateral anterior cingulate
regions (b)
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Cerebral glucose metabolism is affected by the mental
state of the patient. Tashiro et al. [16] reported that pre-
treatment cancer patients exhibit reduced cerebral glucose
metabolism in the prefrontal area, lateral frontal area,
anterior cingulate gyrus, insular cortex and putamen and
that a depressive state may be related to metabolic
abnormalities in these regions. The authors suggested that
brain PET images may help to diagnose psychoneuro-
logical conditions in cancer patients. It has also been
reported that approximately 50 % of cancer patients have
Fig. 3 Images of brain regions
showing significant differences
in cerebral glucose metabolism
between pre-treatment patients
and normal control subjects.
The level of cerebral glucose
metabolism in patients with
lymphoma was significantly
decreased in the bilateral
temporal and left parietal and
bilateral occipital regions
compared to that in the normal
control subjects (a), while it
increased in the right frontal
region and bilateral cerebellar
hemispheres (b)
Table 4 Locations of brain
areas showing an interval
increase in cerebral glucose
metabolism between the normal
groups with patients
examinations
p \ 0.02, uncorrected for
multiple comparisons
a Coordinated in the Talairach
space
Brain regions Cluster size
(no. of voxels)
Peak-level Peak coordinatesa
x, y, z (mm)
puncorr Z x y z
Bil. middle occipital 5,509 \0.02
\0.02
3.88
3.70
-38
-38
-68
-35
5.2
37
Lt. inferior parietal 5,509 \0.02 3.77 38 -62 8.6
Lt. middle frontal 380 \0.02 2.87 -36 39 5.4
956 Ann Nucl Med (2014) 28:950–960
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neuropsychiatric problems fulfilling the DSM-III or DSM-
R criteria III [17, 18], and that the prevalence of a
depressive state in cancer patients ranges from 1.5 [19] to
53 % [20]. Although we were unable to precisely evaluate
the mental state of the patients with malignant lymphoma
due to the limitations of the study design, a subclinical
depressive state may affect cerebral glucose metabolism.
In the present study, cerebral glucose metabolism was
decreased in the bilateral cerebellar hemisphere, right
putamen, bilateral insula and bilateral anterior cingulate
regions after chemotherapy. This reduction in cerebellar
and putamen glucose metabolism may merely reflect the
mirror effect of improved cerebral glucose metabolism.
Meanwhile, the decreased glucose metabolism in the
insula and anterior cingulate gyrus may be related to the
mental state of the patients. On the other hand, it is well
known that chemotherapy using anticancer drugs can
result in brain damage, such as leukoencephalopathy [21].
We found no apparent evidence of leukoencephalopathy
in our patients; however, some cases of brain damage may
have occurred with subsequent decreased cerebral glucose
metabolism.
The plasma glucose level may change the regional dis-
tribution of FDG in the brain as well as the global brain
FDG uptake. Kawasaki et al. reported that the FDG dis-
tribution pattern is altered under conditions of mild
hyperglycemia and that a decreased uptake pattern
resembles to that observed in patients with Alzheimer’s
disease. However, in the present study, there were no sig-
nificant differences in the plasma glucose levels between
the pre- and post-treatment examinations; hence, it is
thought to be unlikely that a decreased regional cerebral
glucose metabolism is caused by changes in the plasma
glucose levels in patients with malignant lymphoma.
Regarding the effect of FDG shift from the brain to the
huge tumor burden, this phenomenon reduces the total
Table 5 Locations of brain
areas showing an interval
decrease in cerebral glucose
metabolism between the normal
groups with patients
examinations
p \ 0.02, uncorrected for
multiple comparisons
a Coordinated in the Talairach
space
Brain regions Cluster size
(no. of voxels)
Peak-level Peak coordinatesa
x, y, z (mm)
puncorr Z x y z
Bil. vermis 1,390 \0.02 2.55 0 -43 -8.9
Lt. cerebellar hemisphere 1,390 \0.02 2.26 18 -33 -22
Lt. middle frontal 380 \0.02 2.87 -36 39 5.4
Rt. inferior frontal 364 \0.02 2.84 59 0 18
Rt. cerebellar hemisphere 339 \0.02 2.60 -20 -81 -27
Fig. 4 (Case 1: diffuse large
B-cell lymphoma, intravascular
lymphoma) FDG-PET images
of the whole body and brain.
Whole-body FDG-PET showed
a high uptake in the liver and
bilateral femoral bone marrow
(a). Brain FDG images
demonstrated a reduction in
glucose metabolism in the
bilateral parieto-occipital
regions (b–d). MRI showed no
abnormalities in the brain (e)
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amount of FDG in the brain, but it is not considered to
affect the regional distribution of FDG in the brain,
because the dose of the carrier FDG is very small
(1 mg).
The limitations of this study include the following. As
this study was retrospectively performed referring to
medical records, the subjects’ mental state and function
were not evaluated objectively. Organic brain lesions were
evaluated primarily using CT with low-dose PET/CT
examinations, except in a small number of patients.
Therefore, some organic lesions of the brain may not have
been detected. In addition, normal control subjects were
neither age matched nor sex matched due to limited
number of normal control subjects at our institute. This
Fig. 5 After chemotherapy, the
abnormal FDG uptake in the
liver and bone marrow
disappeared (a) and the cerebral
glucose metabolism improved
(b–d)
Fig. 6 (Case 2: T-cell
lymphoma). FDG-PET images
of the whole body and brain.
Whole-body FDG-PET showed
a high uptake in the systemic
lymph nodes, spleen and bone
marrow (a). Brain FDG images
demonstrated a reduction in
glucose metabolism in the
bilateral parieto-occipital
regions (b–d). MRI showed no
abnormalities in the brain (e)
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may affect the results of the present study. Regarding the
cerebral glucose metabolism, the absolute values of cere-
bral glucose metabolism were not evaluated in this study,
because it required invasive techniques such as arterial
blood sampling. Thus, our findings of decrease in regional
cerebral glucose metabolism were just relative ones.
In conclusion, we herein demonstrated that patients with
malignant lymphoma of the body exhibit abnormal regio-
nal cerebral glucose metabolism that improves after che-
motherapy. Although the mechanism underlying the
reduction in cerebral glucose metabolism remains unclear,
precise observations of brain data extracted from whole-
body scans may reveal functional alternation or subclinical
damage of the brain in patients with malignant lymphoma
that may have been overlooked in whole-body FDG-PET/
CT studies.
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